These solid data provide proof of concept that topical antiretrovirals can serve as effective anti-HIV microbicides. Given the efficacy and pharmacology of tenofovir in HIV treatment, and the positive ...

Tenofovir decreases HSV-2 risk Oral tenofovir-based prophylaxis for HIV also reduced herpes simplex virus-2 transmission. Daily oral tenofovir-based preexposure prophylaxis (PrEP) for HIV also seemed ...

Prevention—what doesn’t work? In a session entitled “Status of the U.S. HIV/AIDS Epidemic: Is It Changing and If Not, Why Not?” Harold Jaffe, MD, former head of the CDC, discussed a not-yet-published ...

In the last two weeks, widespread posts on social media have claimed there are outbreaks of HIV and herpes at Grand Valley ...

A group of researchers led by Xavier Saelens and Sven Eyckerman at the VIB-UGent Center for Medical Biotechnology discovered how a protein linked to the human immune system wards off HIV-1 and herpes ...

Genital herpes infections are very common. There are 42 million new infections each year — that averages out to one new person infected each second. While treatments can help with symptoms, there's no ...

A World Health Organization (WHO) director has called for “better prevention and treatment options” after the agency released new estimates of genital herpes prevalence. Dr Meg Doherty, director of ...

– Interim proof-of-concept Phase 1b data in participants with recurrent genital herpes expected for both candidates in fall 2025 – “These data presented for ABI-5366 and ABI-1179 continue to support ...

A photomicrograph image of herpes virus antibodies detected using immunofluorescent staining technique, 1977. Image courtesy CDC/Dr. Craig Lyerla. (Photo by Smith Collection/Gado/Getty Images) A ...

Around 846 million people aged between 15 and 49 are living with genital herpes infections – more than 1 in 5 of this age-group globally – according to new estimates released today. At least 1 person ...